Healthcare

Healthcare is a very dynamic and diverse sector and our expertise matches our client base in:-

• Biotechnology
• Pharmaceuticals
• Digital Health
• Medical Technology
• Healthcare Services
• Animal Health

All fuelled by technology and innovation in a rapidly evolving landscape.

  • Advisory

  • Corporate Broking Services

  • Fundraising

  • Growth Capital Solutions

  • IPO and M&A

Healthcare

The team is highly experienced and provides a full service to help our clients achieve their growth ambitions. We have backgrounds in scientific research, strategic consultancy, accountancy and buy-side investment. Panmure Gordon has been one of the most active advisers for fundraising in the sector for over ten years.

Our Clients

Contact Us

Recent Transactions

  • October 2023

    NetScientific

    Corporate Broker

  • October 2023

    Allergy Therapeutics

    £48m

    Sell side M&A Advisory

    Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker

  • July 2023

    BiVictriX Therapeutics plc

    £2.1m

    Fundraise

    Joint Broker

  • April 2023

    Allergy Therapeutics

    £40.7m

    Fundraise

    Financial Adviser, NOMAD & Broker

  • October 2022

    Diurnal Group

    £48m

    Sell side M&A Advisory

    Rule 3 Adviser, Financial Adviser, Nominated Adviser and Corporate Broker

  • September 2022

    Allergy Therapeutics

    £7m

    Fundraise

    Nominated Adviser and Corporate Broker

  • September 2022

    CareTech Holdings

    £870m

    Sell side M&A Advisory

    Rule 3 Adviser, Financial Adviser, Nominated Adviser and Corporate Broker

  • August 2022

    C4X Discovery

    £5.7m

    Fundraise

    Nominated Adviser, Sole Broker and Sole Boookrunner

  • August 2022

    Arecor Therapeutics

    £6m

    Fundraise

    Nominated Adviser & Broker

  • November 2021

    Feedback

    £11.2m

    Fundraise

    Nominated Adviser, Sole Bookrunner and Corporate Broker

  • July 2021

    Animalcare

    £39m

    Fundraise

    Joint Broker

  • June 2021

    Arecor

    £62.5m

    IPO and Fundraise

    Nominated Adviser, Financial Adviser and Sole Broker

  • May 2021

    Diurnal

    £20m

    Fundraise

    Nominated Adviser and Sole Corporate Broker

  • February 2021

    MaxCyte. Inc

    £40m

    Fundraise

    Nominated Adviser and Joint Broker

  • November 2020

    C4X Discovery Holdings

    £15m

    Fundraise

    Nominated Adviser and Sole Corporate Broker

  • November 2020

    Scancell Holdings

    £33m

    Fundraise

    Nominated Adviser and Sole Corporate Broker

  • August 2020

    Scancell Holdings

    £15m

    Fundraise

    Nominated Adviser and Corporate Broker

  • May 2020

    MaxCyte, Inc.

    £25.1m

    Fundraise

    Nominated Adviser, Joint Broker and Joint Bookrunner

  • April 2020

    Faron Pharmaceuticals

    £12m

    Fundraise

    Nominated Adviser and Sole Broker

  • March 2020

    Diurnal Group

    £11.2m

    Fundraise

    Nominated Adviser and Joint Broker

Discover who else we help

View all

Contact Panmure Gordon

Contact us +44 (0)20 7886 2500